Blockchain Registration Transaction Record

Cardio Diagnostics Brings Molecular Precision to CHD Detection

Cardio Diagnostics Holdings (NASDAQ: CDIO) introduces epigenetic and genetic tests to improve coronary heart disease detection, addressing the blind spot where 50% of cases lack traditional risk factors.

This news matters because coronary heart disease is the leading cause of death, yet current screening tools miss half of cases. Cardio Diagnostics' epigenetic and genetic tests could revolutionize early detection, potentially saving lives by identifying at-risk individuals who appear healthy. For patients and healthcare providers, this means moving beyond outdated checklists to a more accurate, molecular-level understanding of heart disease risk, enabling earlier intervention and prevention of cardiac events.